Nationwide Fund Advisors boosted its holdings in shares of Nabriva Therapeutics AG (NASDAQ:NBRV) by 4.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 180,924 shares of the biotechnology company’s stock after purchasing an additional 7,924 shares during the period. Nationwide Fund Advisors owned about 6.65% of Nabriva Therapeutics AG worth $2,032,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Wellington Management Group LLP raised its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after acquiring an additional 193,951 shares during the period. 50.23% of the stock is owned by institutional investors.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 6,585 shares of the firm’s stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $10.51, for a total value of $69,208.35. Following the completion of the sale, the insider now owns 2,391,177 shares in the company, valued at $25,131,270.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Monday, September 18th. The stock was bought at an average price of $9.46 per share, with a total value of $497,889.26. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 57,219 shares of company stock valued at $535,919 and sold 195,670 shares valued at $1,983,641. 2.75% of the stock is owned by company insiders.
Nabriva Therapeutics AG (NASDAQ NBRV) opened at 7.38 on Monday. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $14.10. The firm has a 50 day moving average of $8.37 and a 200-day moving average of $9.76. The firm’s market cap is $198.06 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million. On average, equities research analysts forecast that Nabriva Therapeutics AG will post ($2.29) earnings per share for the current year.
A number of research analysts have weighed in on NBRV shares. Cantor Fitzgerald set a $16.00 price objective on shares of Nabriva Therapeutics AG and gave the stock a “buy” rating in a research report on Tuesday, July 11th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a research report on Friday, June 30th. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Thursday, August 10th. SunTrust Banks, Inc. started coverage on shares of Nabriva Therapeutics AG in a research report on Friday, August 25th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price objective (up previously from $15.00) on shares of Nabriva Therapeutics AG in a research report on Tuesday, September 19th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $18.78.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
What are top analysts saying about Nabriva Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics AG and related companies.